Sumain Faisal

Gilead’s Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates. Latest Ratings for GILD Date Firm Action From To Mar 2022 Barclays Maintains Underweight Mar 2022 RBC Capital Maintains Outperform Feb 2022 BMO Capital Downgrades Outperform Market Perform View More Analyst Ratings…

Read More